Shares of Reckitt Benckiser Group plc (OTCMKTS:RBGLY - Get Free Report) have earned a consensus rating of "Buy" from the eight research firms that are currently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and four have given a strong buy rating to the company.
RBGLY has been the topic of several analyst reports. Barclays raised Reckitt Benckiser Group to a "strong-buy" rating in a research report on Friday, October 4th. Citigroup raised shares of Reckitt Benckiser Group to a "strong-buy" rating in a research note on Tuesday, October 1st. Sanford C. Bernstein downgraded shares of Reckitt Benckiser Group from a "strong-buy" rating to a "hold" rating in a report on Monday, November 4th. HSBC raised shares of Reckitt Benckiser Group from a "hold" rating to a "buy" rating in a research report on Wednesday, December 11th. Finally, UBS Group raised Reckitt Benckiser Group to a "strong-buy" rating in a research note on Wednesday, September 18th.
Check Out Our Latest Stock Analysis on Reckitt Benckiser Group
Reckitt Benckiser Group Trading Up 0.3 %
RBGLY stock traded up $0.03 during midday trading on Wednesday, reaching $12.02. 270,358 shares of the company traded hands, compared to its average volume of 841,086. Reckitt Benckiser Group has a 52-week low of $10.24 and a 52-week high of $15.03. The business has a 50 day moving average of $12.27 and a 200-day moving average of $11.80. The company has a current ratio of 0.69, a quick ratio of 0.47 and a debt-to-equity ratio of 0.97.
About Reckitt Benckiser Group
(
Get Free ReportReckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
See Also
Before you consider Reckitt Benckiser Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reckitt Benckiser Group wasn't on the list.
While Reckitt Benckiser Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
